|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C6orf141 |
Gene summary for C6ORF141 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C6orf141 | Gene ID | 135398 |
| Gene name | chromosome 6 open reading frame 141 | |
| Gene Alias | C6orf141 | |
| Cytomap | 6p12.3 | |
| Gene Type | protein-coding | GO ID | GO:0001701 | UniProtAcc | A0A024RD72 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 135398 | C6orf141 | GSM4909297 | Human | Breast | IDC | 3.91e-09 | 5.35e-01 | 0.1517 |
| 135398 | C6orf141 | GSM4909301 | Human | Breast | IDC | 1.67e-03 | 2.72e-01 | 0.1577 |
| 135398 | C6orf141 | GSM4909312 | Human | Breast | IDC | 4.64e-06 | 3.11e-01 | 0.1552 |
| 135398 | C6orf141 | GSM4909319 | Human | Breast | IDC | 1.19e-02 | -2.76e-02 | 0.1563 |
| 135398 | C6orf141 | brca10 | Human | Breast | Precancer | 3.69e-04 | 2.68e-01 | -0.0029 |
| 135398 | C6orf141 | M1 | Human | Breast | IDC | 1.24e-03 | 3.34e-01 | 0.1577 |
| 135398 | C6orf141 | NCCBC2 | Human | Breast | DCIS | 1.54e-11 | 9.14e-01 | 0.1554 |
| 135398 | C6orf141 | P2T-E | Human | Esophagus | ESCC | 3.16e-05 | -9.73e-02 | 0.1177 |
| 135398 | C6orf141 | P5T-E | Human | Esophagus | ESCC | 1.89e-08 | 9.54e-02 | 0.1327 |
| 135398 | C6orf141 | P11T-E | Human | Esophagus | ESCC | 3.43e-02 | 3.09e-01 | 0.1426 |
| 135398 | C6orf141 | P12T-E | Human | Esophagus | ESCC | 3.77e-08 | -3.55e-02 | 0.1122 |
| 135398 | C6orf141 | P16T-E | Human | Esophagus | ESCC | 5.19e-04 | -2.51e-02 | 0.1153 |
| 135398 | C6orf141 | P21T-E | Human | Esophagus | ESCC | 1.55e-08 | 5.25e-02 | 0.1617 |
| 135398 | C6orf141 | P26T-E | Human | Esophagus | ESCC | 3.71e-13 | 3.06e-01 | 0.1276 |
| 135398 | C6orf141 | P28T-E | Human | Esophagus | ESCC | 8.46e-05 | -5.27e-02 | 0.1149 |
| 135398 | C6orf141 | P31T-E | Human | Esophagus | ESCC | 5.66e-05 | -9.92e-02 | 0.1251 |
| 135398 | C6orf141 | P37T-E | Human | Esophagus | ESCC | 2.59e-06 | 1.41e-01 | 0.1371 |
| 135398 | C6orf141 | P42T-E | Human | Esophagus | ESCC | 8.94e-03 | 6.95e-02 | 0.1175 |
| 135398 | C6orf141 | P48T-E | Human | Esophagus | ESCC | 1.49e-03 | -1.09e-01 | 0.0959 |
| 135398 | C6orf141 | P49T-E | Human | Esophagus | ESCC | 2.05e-12 | 2.66e+00 | 0.1768 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00017017 | Breast | Precancer | in utero embryonic development | 35/1080 | 367/18723 | 2.47e-03 | 2.27e-02 | 35 |
| GO:000170113 | Breast | IDC | in utero embryonic development | 42/1434 | 367/18723 | 5.85e-03 | 4.24e-02 | 42 |
| GO:000170122 | Breast | DCIS | in utero embryonic development | 41/1390 | 367/18723 | 5.74e-03 | 4.13e-02 | 41 |
| GO:000170119 | Esophagus | ESCC | in utero embryonic development | 243/8552 | 367/18723 | 1.00e-15 | 6.86e-14 | 243 |
| GO:000182412 | Esophagus | ESCC | blastocyst development | 73/8552 | 106/18723 | 1.13e-06 | 1.40e-05 | 73 |
| GO:000170116 | Oral cavity | OSCC | in utero embryonic development | 207/7305 | 367/18723 | 7.92e-12 | 2.95e-10 | 207 |
| GO:00018243 | Oral cavity | OSCC | blastocyst development | 66/7305 | 106/18723 | 1.04e-06 | 1.40e-05 | 66 |
| GO:000170124 | Skin | cSCC | in utero embryonic development | 150/4864 | 367/18723 | 2.47e-10 | 1.04e-08 | 150 |
| GO:000182413 | Skin | cSCC | blastocyst development | 53/4864 | 106/18723 | 9.74e-08 | 2.32e-06 | 53 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C6orf141 | SNV | Missense_Mutation | c.598N>C | p.Glu200Gln | p.E200Q | Q5SZD1 | protein_coding | deleterious(0.01) | possibly_damaging(0.64) | TCGA-BH-A0EB-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| C6orf141 | SNV | Missense_Mutation | novel | c.343G>A | p.Asp115Asn | p.D115N | Q5SZD1 | protein_coding | deleterious(0.04) | benign(0.257) | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| C6orf141 | SNV | Missense_Mutation | c.364N>C | p.Glu122Gln | p.E122Q | Q5SZD1 | protein_coding | tolerated(0.22) | benign(0.01) | TCGA-R2-A69V-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| C6orf141 | SNV | Missense_Mutation | c.261N>T | p.Glu87Asp | p.E87D | Q5SZD1 | protein_coding | tolerated(0.25) | benign(0.024) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| C6orf141 | SNV | Missense_Mutation | c.401N>A | p.Phe134Tyr | p.F134Y | Q5SZD1 | protein_coding | tolerated(0.37) | benign(0.033) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| C6orf141 | SNV | Missense_Mutation | c.110N>T | p.Gly37Val | p.G37V | Q5SZD1 | protein_coding | deleterious(0.01) | possibly_damaging(0.718) | TCGA-G4-6314-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Ancillary | leucovorin | SD | |
| C6orf141 | SNV | Missense_Mutation | novel | c.176N>A | p.Gly59Asp | p.G59D | Q5SZD1 | protein_coding | tolerated(0.17) | benign(0.012) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| C6orf141 | SNV | Missense_Mutation | novel | c.44N>A | p.Gly15Glu | p.G15E | Q5SZD1 | protein_coding | tolerated(0.08) | possibly_damaging(0.728) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C6orf141 | SNV | Missense_Mutation | novel | c.190N>A | p.Asp64Asn | p.D64N | Q5SZD1 | protein_coding | tolerated(0.28) | benign(0.005) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| C6orf141 | SNV | Missense_Mutation | rs771175194 | c.622N>T | p.Gly208Cys | p.G208C | Q5SZD1 | protein_coding | deleterious_low_confidence(0.01) | benign(0.325) | TCGA-AP-A05O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |